Advances in diagnosis and treatment in patients with pulmonary arterial hypertension

Catheterization and Cardiovascular Interventions

Volumn 71, Issue 2, 2008, Pages 205-213

  Park, Myung H ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Endothelin receptor antagonist; Hemodynamics; Phosphodiesterase inhibitor; Prostacyclin; Pulmonary hypertension; Right heart

Indexed keywords

AMBROSENTAN; ANALGESIC AGENT; ANTIINFLAMMATORY AGENT; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; CYCLIC GMP; CYCLOSPORIN; DIGOXIN; DIURETIC AGENT; ENDOTHELIN; ENDOTHELIN RECEPTOR ANTAGONIST; GLIBENCLAMIDE; ILOPROST; LETAIRIS; NITRIC OXIDE; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PROSTACYCLIN; PROSTANOID; SILDENAFIL; SITAXSENTAN; UNCLASSIFIED DRUG; UNIPROST; WARFARIN;

CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; COUGHING; DIARRHEA; DISEASE CLASSIFICATION; DISEASE COURSE; DOPPLER ECHOCARDIOGRAPHY; DRUG ANTAGONISM; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; EDEMA; EPISTAXIS; FLUSHING; FOOD AND DRUG ADMINISTRATION; HEADACHE; HEART CATHETERIZATION; HUMAN; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; LEG PAIN; LIVER DISEASE; MONOTHERAPY; NAUSEA; NONHUMAN; NOSE CONGESTION; PAIN; PATHOGENESIS; PERIPHERAL EDEMA; PROTEIN FUNCTION; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; SINUSITIS; SYSTOLIC BLOOD PRESSURE; UNSPECIFIED SIDE EFFECT; VISUAL DISORDER;

ANTIHYPERTENSIVE AGENTS; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; ENDOTHELIUM, VASCULAR; EPOPROSTENOL; HEART CATHETERIZATION; HEART FAILURE; HUMANS; HYPERTENSION, PULMONARY; ILOPROST; ISOXAZOLES; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PLATELET AGGREGATION INHIBITORS; PROGNOSIS; PULMONARY ARTERY; PURINES; RECEPTORS, ENDOTHELIN; SULFONAMIDES; SULFONES; THIOPHENES; VASOCONSTRICTION;

EID: 39749173306     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.21389     Document Type: Review

References (60)

1. Farber HW, Loscalzo J. Mechanisms of disease: Pulmonary arterial hypertension. N Engl J Med 2004;351:1655-1665.
2. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension: A national prospective study. Ann Intern Med 1987;107:216-223.
3. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension: Results from a national prospective registry. Ann Intern Med 1991;115:343-349.
4. Rubin LJ. Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004;126:7S-10S.
5. Wigley FM, Lima JA, Mayes M, et al. The prevalence of undiagnosed pulmonary arterial hypertension in subjects with connective tissue disease at the secondary health care level of community-based rheumatologists (the UNCOVER study). Arthritis Rheum 2005;52:2125-2132.
6. Koh ET, Lee P, Gladman DD, et al. Pulmonary hypertension in systemic sclerosis: An analysis of 17 patients. Br J Rheumatol 1996;35:989-993.
7. Kuhn KP, Byrne DW, Arbogast PG, et al. Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol. Am J Respir Crit Care Med 2003;167:580-586.
8. Raymond RL, Hinderliter AL, Willis PW, et al. Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension. J Am Coll Cardiol 2002;39:1214-1219.
9. Currie PJ, Seward JB, Chan KL, et al. Continuous wave Doppler determination of right ventricular pressure: A simultaneous Doppler- catheterization study in 127 patients. J Am Coll Cardiol 1985;6:750-756.
10. Arcasoy SM, Christie JD, Ferrari VA, et al. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am J Respir Crit Care Med 2003;167:735-740.
11. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: The impact of epoprostenol therapy. Circulation 2002;106:1477-1482.
12. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: Prognostic factors and survival. J Am Coll Cardiol 2002;40:780-788.
13. Sitbon O, Humbert M, Jais X, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005;111:3105-3111.
14. Sitbon O, Humbert M, Jagot JL, et al. Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension. Eur Respir J 1998;12:265-270.
15. Groves BM, Badesch DB, Turkevich D, et al. Correlation of acute prostacyclin response in primary (unexplained) pulmonary hypertension with efficacy of treatment with calcium channel blockers and survival. In: Weir K, editor. Ion Flux in Pulmonary Vascular Control. New York, NY: Plenum Press; 1993. pp 317-330.
16. Schrader BJ, Inbar S, Kaufmann L, et al. Comparison of the effects of adenosine and nifedipine in pulmonary hypertension. J Am Coll Cardiol 1992;19:1060-1064.
17. Hoeper MM, Lee SH, Voswinckel R, et al. Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. J Am Coll Cardiol 2006;48:2546-2552.
18. McGoon M, Gutterman D, Steen V, et al. Screening, early detection, and diagnosis of pulmonary arterial hypertension. ACCP evidence-based clinical practice guidelines. Chest 2004;126:14S-34S.
19. Jamieson SW, Kapelanski DP, Sabakibara N, et al. Pulmonary endarterectomy: Experience and lessons learned in 1,500 cases. Ann Thorac Surg 2003;76:1457-1462.
20. Fedullo PF, Auger WR, Kerr KM, Rubin LJ. Chronic thromboembolic pulmonary hypertension. N Engl J Med 2001;345:1465-1472.
21. Miyamoto S, Nagaya N, Satoh T, et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension: Comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 2000;161:487-492.
22. Nagaya N, Nishikimi T, Uematsu M, et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 2000;102:865-870.
23. Park MH, Scott RL, Uber PA, Ventura HO, Mehra MR. Usefulness of B-type natriuretic peptide as a predictor of treatment outcome in pulmonary arterial hypertension. Congest Heart Fail 2004;10:221-225.
24. Andreassen A, Wergeland R, Simonson S, et al. N-terminal pro-B-type natriuretic peptide as an indicator of disease severity in a heterogeneous group of patients with chronic precapillary pulmonary hypertension. Am J Cardiol 2006;98:525-529.
25. Voekel NF, Truder RM, Weir EK. Pathophysiology of primary pulmonary hypertension. In. Rubin L, Rich S, editors. Primary Pulmonary Hypertension. New York: Marcel Dekker; 1997. pp 83-129.
26. Machado RD, James V, Southwood M, et al. Investigation of second genetic hit at the BMPR2 locus as a modulator of disease progression in familial pulmonary arterial hypertension. Circulation 2005;111:607-613.
27. Yuan JXJ, Rubin LJ. Pathogenesis of pulmonary arterial hypertension: The need for multiple hits. Circulation 2005;111:534-538.
28. Lane KB, Machado RD, Pauciulo MW, et al. Heterozygous germline mutations in BMPR2, encoding a TGF-β receptor, cause familial primary pulmonary hypertension: The International PPH Consortium. Nat Genet 2000;26:81-84.
29. Deng Z, Morse JH, Slager SL, et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet 2000;67:737-744.
30. Christman BW, McPherson CD, Newman JH, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 1992;327:70-75.
31. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332:411-415.
32. Giad A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993;328:1732-1739.
33. Vincent JA, Ross RD, Kassab J, et al. Relation of elevated plasma endothelin in congenital heart disease to increased pulmonary blood flow. Am J Cardiol 1993;71:1204-1207.
34. Ogawa Y, Nakao K, Arai H, et al. Molecular cloning of a non-isopeptide-selective human endothelin receptor. Biochem Biophys Res Commun 1991;178:248-255.
35. Bauer M, Wilkens H, Langer F, et al. Selective upregulation of endothelin B receptor gene expression in severe pulmonary hypertension. Circulation 2002;105:1034-1036.
36. Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 1995;333:214-221.
37. Michelaskis ED, Tymchk W, Noga M, et al. Long term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation 2003;108:2066-2069.
38. Rich S, Kaugmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992;327:76-81.
39. Badesch DB, Abman SH, Ahearn GS, et al. Medical therapy for pulmonary arterial hypertension. ACCP evidence-based clinical practice guidelines. Chest 2004;126:35S-62S.
40. Fuster V, Steele PM, Edwards WD, et al. Primary pulmonary hypertension: Natural history and the importance of thrombosis. Circulation 1984;70:580-587.
41. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996;334: 296-302.
42. Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease: A randomized, controlled trial. Ann Intern Med 2000;132:425-434.
43. Humbert M, Maitre S, Capron F, et al. Pulmonary edema complicating continuous intravenous prostacyclin in pulmonary capillary hemangiomatosis. Am J Respir Crit Care Med 1998;157:1681-1685.
44. Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analog, in patients with pulmonary arterial hypertension: A double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002;165:800-804.
45. Lang I, Gomez-Sanchez M, Kneussl M, et al. Efficacy of long-term subcutaneous treprostinil sodium therapy in pulmonary hypertension. Chest 2006;129:1636-1643.
46. Barst RJ, Galie N, Naeije R, et al. Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil. Eur Respir J 2006;28:1195-1203.
47. Tapson VF, Gomberg-Maitland M, McLaughlin VV, et al. Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: A prospective, multicenter, open-label, 12-week trial. Chest 2006;129:683-688.
48. Centers for Disease Control Report. Bloodstream infections among patients treated with intravenous epoprostenol or intravenous treprostinil for pulmonary hypertension - Seven Sites, United States, 2003-2006. MMWR Morb Mortal Wkly Rep 2007;56:170-172.
49. Voswinckel R, Enke B, Reichenberger F, et al. Favorable effects of inhaled treprostinil in severe pulmonary hypertension: Results from randomized controlled pilot studies. J Am Coll Cardiol 2006;48:1672-1681.
50. Olschewski H, Simonneau G, Galie N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002;347:322-329.
51. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903.
52. McLaughlin VV, Sitbon O, Badesch DB, et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J 2005;25:244-249.
53. Highlights of prescribing information Letairis. Available at: http://www.gilead.com/pdf/letairis_pi.pdf.
54. Galie N, Badesch D, Oudiz R, et al. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2005;46:529-535.
55. Oudiz RJ, Torres F, Frost AE, et al. ARIES-1: A placebo-controlled, efficacy and safety study of ambrosentan in patients with pulmonary arterial hypertension. Chest 2006;130:121S-a.
56. Bartst RJ, Langleben D, Frost A, et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 2004;169:441-447.
57. Barst RJ, Langleben D, Badesch D, et al. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol 2006;47:2049-2056.
58. Galie N, Ghofrani HA, Torbicki A, et al. Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005;353:2148-2157.
59. Paul GA, Gibbs JS, Boobis AR, et al. Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension. Br J Clin Pharmacol 2005;60:107-112.
60. McLaughlin VV, McGoon MD. Pulmonary arterial hypertension. Circulation 2006;114:1417-1431.